Autres langues ALX Oncology Holdings Inc.

Actions

ALXO

US00166B1052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
16,86 ^USD	-0,06%		+8,08%	+13,23%

18/04	Un initié d'Alx Oncology Holdings a vendu des actions d'une valeur de 710 195 $, selon un récent dépôt auprès de la SEC	MT
10/04	ALX Oncology rapporte des données positives de l'essai de phase 1/2 en cours sur l'evorpacept	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	24/04
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	18/04
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	10/04
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	09/04
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	09/04
ALX Oncology : Corporate Presentation	11/03
North American Morning Briefing : Stock Futures -2-	11/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	07/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
ALX Oncology Holdings Inc. and ALX Oncology Inc. Enter into the Third Amendment to Loan and Security Agreement	26/12
North American Morning Briefing : Investors Await -2-	11/12
Top Midday Gainers	08/12
Sector Update: Health Care Stocks Advance Premarket Tuesday	14/11
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	13/11
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	13/11
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ALX Oncology Holdings Inc.

Actions

ALXO

US00166B1052

Autres langues

Filtres